Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection

Clinical and Experimental Allergy

Volumn 37, Issue 2, 2007, Pages 197-207

  Cruz, A A ^a,e   Lima, F ^a   Sarinho, E ^b   Ayre, G ^c   Martin, C ^c   Fox, H ^c   Cooper, P J ^d  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^d Hospital Pedro Vicente Maldonado   (Ecuador)

^e Centro de Saúde Carlos Gomes   (Brazil)

Author keywords

Allergic rhinitis; Asthma; Geohelminth infections; Immunoglobulin E; Monoclonal antibody; Omalizumab

Indexed keywords

ALBENDAZOLE; ANTHELMINTIC AGENT; ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; IMMUNOGLOBULIN E ANTIBODY; IVERMECTIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB; OXAMNIQUINE; PLACEBO; PRAZIQUANTEL; STEROID;

ABDOMINAL PAIN; ABORTION; ADOLESCENT; ADULT; AGE DISTRIBUTION; ALLERGIC ASTHMA; ANXIETY; ARTICLE; ASTHMA; BLOOD DISEASE; BREAST DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EAR DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; HELMINTH; HELMINTHIASIS; HUMAN; HYPOTENSION; INFECTION; INFECTION RISK; INFESTATION; INNER EAR DISEASE; INTESTINE INFECTION; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; METABOLIC DISORDER; MORBIDITY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PERENNIAL RHINITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RESPIRATORY TRACT DISEASE; RHINITIS; SCHOOL CHILD; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; THORAX DISEASE; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR DISEASE;

ADOLESCENT; ADULT; ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CHILD; DRUG COMBINATIONS; FEMALE; HELMINTHIASIS; HUMANS; IMMUNOGLOBULIN E; IMMUNOLOGIC FACTORS; MALE; RHINITIS, ALLERGIC, PERENNIAL; RISK FACTORS;

EID: 33846464598     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2007.02650.x     Document Type: Article

References (29)

1. Savioli L, Albonico M. Soil-transmitted helminthiasis. Nat Rev Microbiol 2004; 2:618-9.
2. Bundy DAP, Chan MS, Medley GF, Jamison D. Intestinal nematode infections. In: Murray CJL, Lopez AD, Athers CD, eds. The global epidemiology of infectious diseases. Geneva: World Health Organization, 2004; 243-300.
3. Jarrett EE, Miller HR. Production and activities of IgE in helminth infection. Prog Allergy 1982; 31:178-233.
4. Cooper PJ, Nutman TB. IgE and its role in parasitic helminth infection. In: Fick RB, Jardieu P, eds. IgE and anti-IgE therapy in asthma and allergic disease, lung biology in health and disease. New York: Marcel Dekker, 2002; 54-61.
5. Finkelman FD, Shea-Donohue T, Morris SC et al. Interleukin-4-and interleukin-13-mediated host protection against intestinal nematode parasites. Immunol Rev 2004; 201:139-55.
6. Loukas A, Prociv P. Immune responses in hookworm infections. Clin Microbiol Rev 2001; 14:689-703.
7. Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003; 91:182-8.
8. Buhl R, Solèr M, Matz J et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002; 20:73-8.
9. Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-90.
10. Genentech Inc, Novartis Pharmaceutical Corporation., Xolair® prescribing information. 2003.
11. Holgate ST, Chuchalin AG, Hébert J et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632-8.
12. Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003; 91:154-9.
13. Solèr M, Matz J, Townley R et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-61.
14. Vignola AM, Humbert M, Bousquet J et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59:709-17.
15. MacGlashan DW Jr., Bochner BS, Adelman DC et al. Downregulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158:1438-45.
16. de Silva N, Guyatt H, Bundy D. Anthelmintics. A comparative review of their clinical pharmacology. Drugs 1997; 53:769-88.
17. WHO., Diagnostic techniques for intestinal parasitic infections (IPI) applicable to primary health care (PHC) services. WHO/PDP/85.2. 1985.
18. Watson JM, Al-Hafidh R. A modification of the Baermann funnel technique and its use in establishing the infection potential of human hookworm carriers. Ann Trop Med Parasitol 1957; 41:15-6.
19. Porto AF, Oliveira FJ, Neva FA et al. Influence of human T-cell lymphocytotropic virus type 1 infection on serologic and skin tests for strongyloidiasis. Am J Trop Med Hyg 2001; 65:610-3.
20. Belizario VY, Amarillo ME, de Leon WU, los Reyes AE, Bugayong MG, Macatangay BJ. A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp. Bull World Health Organ 2003; 81:35-42.
21. Cooper PJ, Chico ME, Rodrigues LC et al. Reduced risk of atopy among school-age children infected with geohelminth parasites in a rural area of the tropics. J Allergy Clin Immunol 2003; 111:995-1000.
22. Cooper PJ, Chico ME, Bland M, Griffin GE, Nutman TB. Allergic symptoms, atopy, and geohelminth infections in a rural area of Ecuador. Am J Respir Crit Care Med 2003; 168:313-7.
23. Allen JE, Maizels RM. Immunology of human helminth infection. Int Arch Allergy Immunol 1996; 109:3-10.
24. Butterworth AE, Dunne DW, Fulford AJ, Ouma JH, Sturrock RF. Immunity and morbidity in Schistosoma mansoni infection: quantitative aspects. Am J Trop Med Hyg 1996; 55 (suppl):109-15.
25. Capron M, Capron A. Immunoglobulin E and effector cells in schistosomiasis. Science 1994; 264:1876-7.
26. Bell RG. IgE, allergies and helminth parasites: a new perspective on an old conundrum. Immunol Cell Biol 1996; 74:337-45.
27. Moqbel R, Pritchard DI. Parasites and allergy: evidence for a 'cause and effect' relationship. Clin Exp Allergy 1990; 20:611-8.
28. Finkelman FD, Shea-Donohue T, Goldhill J et al. Cytokine regulation of host defense against parasitic gastrointestinal nematodes: lessons from studies with rodent models. Annu Rev Immunol 1997; 15:505-33.
29. Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev 2004; 17:208-17.